

September 14, 2020

BSE Limited

Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001

<u>Scrip code: 532531</u>

The National Stock Exchange of India Limited

Exchange Plaza , Bandra-Kurla Complex

Bandra (E) Mumbai - 400 051

Scrip code: STAR

Dear Sirs,

Sub: Strides Press Release dated September 14, 2020 titled "Strides unveils SteriScience as its dedicated arm for sterile injectables"

With reference to above, please also find enclosed the disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 on the said transaction.

Thanks and Regards,

For Strides Pharma Science Limited

Manjula Ramamurthy Company Secretary



Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Strides unveils SteriScience as its dedicated arm for sterile injectables

Sr. No	Particulars	Remarks
1.	Name of the Target entity, details in brief such as size, turnover etc.	SteriScience Pharma Private Limited ('SteriScience') is a newly incorporated company by Strides' Promoters family office
2.	Whether the acquisition of the Target entity falls within the related party Transaction and whether the promoter/ promoter group/group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length"	on August 29, 2020. Consequently, Mr. Arun Kumar, Founder and Chairperson of Strides is interested in SteriScience.
3.	Industry to which Target entity being acquired belongs	Pharmaceuticals (Injectibles)
4.	Objects and effects of acquisition	Investment in SteriScience will allow Strides to leverage its rich expertise and experience in the high-value injectables business. SteriScience is designed for a global foray in sterile injectables leveraging the group's rich experience in the domain. It will be a lighter, faster and yet more valuable platform with a robust B2C strategy that bodes well with the industry opportunity.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	None





6.	Indicative time period for completion of the acquisition	Investment to be made over a period of 24 months
7.	Nature of consideration - Whether cash consideration or share swap and details of the same.	Cash Consideration
8.	Cost of acquisition or the price at which the shares are acquired	Strides to invest INR 1,350 Million over the next 24 months
9.	Percentage of shareholding/ control acquired and/ or number of shares acquired	Strides to have a controlling stake in SteriScience with ~54% ownership
10.	Brief background about the entity acquired	d in terms of:
a.	Products/ line of business acquired	Injectables
b.	Date of incorporation	August 29, 2020
c.	History of last 3 years turnover	Not Applicable as SteriScience is a newly incorporated Company.
d.	Country in which the acquired entity has presence	India
e.	Any other significant information	-

